Duloxetine chemical structure of duloxetine
Find information on thousands of medical conditions and prescription drugs.

Duloxetine

Duloxetine hydrochloride (brand names: Cymbalta/Yentreve) is a medically used drug that primarily targets major depressive disorders (MDD), pain related to diabetic peripheral neuropathy and stress urinary incontinence (SUI). Known also as LY248686, chemically (+)-(S)-N-methyl-3-(1-naphthyloxy)-
2-thiophenepropanamine, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE and 5-HT transport sites. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Its behavior contrasts to most other dual-reuptake inhibitors in that Ki values are nearly 1:1.

Furthermore, duloxetine lacks affinity for monoamine receptors within the central nervous system. While there is limited data available regarding the pharmacokinetic profile of duloxetine in humans, its half-life is reported to be 10 to 15 hours. Most common side effects in clinical trials were nausea, somnolence, and dry mouth. In clinical trials weight gain was neutral compared to placebo. Ongoing studies including a 52 week safety and efficacy trial are available at www.lillytrials.com. Long-term side-effects seen in these trials did not vary from the original approval studies.

Duloxetine is also approved by the FDA for the treatment of diabetic neuropathy. Approved dosages for treatment diabetic peripheral neuropathic pain are 60mg and 120mg once daily.

When used for the treatment of depression, the approved dosage is 40mg-60 mg once daily. Duloxetine is available in capsules of 20mg, 30mg, and 60mg.

Read more at Wikipedia.org


[List your site here Free!]


Too much of a good thing: acute eosinophilic pneumonia with a "new" anti-depressant
From CHEST, 10/1/05 by Antonio V. Salud, II

INTRODUCTION: The incidence of acute eosinophilic pneumonia (AEP) among patients admitted with presumed community acquired pneumonia is uncertain, but AEP associated with shock is rare. [1] Medications can cause AEP with the pathophysiology attributed to acute hypersensitivity. [2] We report AEP possibly caused by duloxetine.

CASE PRESENTATION: A 30 year old Caucasian woman was admitted with five day history of fever, chills, dyspnea, cough, and nausea. She was diagnosed with pneumonia by chest x-ray and prescribed antibiotics one day prior to admission. Past medical history was significant for depression and chronic prescription narcotic use secondary to back pain. She was recently institutionalized for depression, weaned off narcotics, and prescribed duloxetine. Medications on admission were azithromycin, duloxetine, vitamin B12, multivitamin, and Garlic. She denied tobacco use but drank alcohol heavily prior to hospitalization for depression. She had no history of IV drug abuse or HIV exposures. She denied occupational, chemical, dust, or asbestos exposures. She had a parrot for five years, but no recent travel. On admission, the patient was in "mild distress" with temperature of 39.5[degrees]C, blood pressure 95/55 mmHg, heart rate 144 bpm, and respiratory rate 20. Her SpO2 was 90% on room air. Lung exam revealed diffuse crackles. She had 20.4 [10.sup.3]/uL white blood cells with 86% segmented neutrophils. Comprehensive metabolic panel and lactate were within normal limits. Admission ABG showed pH 7.44, PaCO2 30 mmHg, PaO2 49 mmHg and SaO2 84%. Blood cultures were ordered. The admission chest x-ray showed worsening consolidation bilaterally. She was placed on 4 liters oxygen, and ad-ministered ceftriaxone combined with azithromycin. The following day, her clinical course deteriorated with development of respiratory failure and shock. She was intubated and treated with vasopressors. Bronchoalveolar lavage showed no pathogens by stain or culture but revealed 80% eosinophils. Duloxetine was discontinued and methylprednisolone started. Antibiotics and vasopressors were discontinued after two days; the patient was extubated in three. She developed peripheral eosinophilia while still receiving methylprednisolone. She was discharged after eight hospital days on prednisone, fluoxetine, and gabapentin. As an outpatient, eosinophilia resolved then recurred. Eosinophilia finally normalized after fluoxetine was discontinued. Three weeks after discharge, repeat chest x-ray was normal and she was doing Pilates.

DISCUSSIONS: Acute eosinophilic pneumonia was first described as "double pneumonia" with respiratory failure.[3] The AEP diagnostic criteria[4] are: (1) Acute febrile illness < 5 days duration, (2) Hypoxemic respiratory failure, (3) Diffuse alveolar or mixed alveolar-interstitial chest X-ray infiltrates, (4) BAL eosinophils > 25%, (5) Absence of parasitic, fungal, or other infection, (6) Prompt and complete response to corticosteroids, (7) Failure to relapse after discontinuation of corticosteroids. This case fulfills these criteria, with duloxetine and secondarily fluoxetine the inciting agents. Medications are well known causes of eosinophilic pneumonia.[5] Venlafaxine was reported as an inciting agent in 2000. [6] Duloxetine and venlafaxine are similar in mechanism and pharmacodynamics. [7].

CONCLUSION: This may be the first report linking duloxetine with AEP. Cessation of exposure and corticosteroid treatment produced prompt and complete resolution of severe respiratory failure. The diagnosis of AEP was made only by bronchoalveolar lavage, emphasizing the importance of bronchoscopy in selected patients despite the risk imposed by severe hypoxemia.

REFERENCES:

[1] Buddharaju VL et al, Acute eosinophilic pneumonia associated with shock, Crit Care Med 1999;27(9):2014-2016.

[2] Badesch DB et al, Acute eosinophilic pneumonia: a hypersensitivity phenomenon? Amer Rev Respir Dis 1989;139:249-52.

[3] Ibid.

[4] Allen JN and Davis WB, Eosinophilic Lung Diseases, Am J Respir Crit Care Med 1994;150:1423-1438.

[5] http://www.pneumotox.com/indexf.php?fich=clin0&lg=en

[6] Fleisch MC et al, Eosinophilic pneumonia and respiratory failure associated with venlafaxine treatment, Eur Respir J 2000;15:205-208.

[7] Sharma A et al, Pharmacokinetics and Safety of Duloxetine, a Dual-Serotonin and Norepinephrine Reuptake Inhibitor, J Clin Pharmacol 2000;40:161-167.

DISCLOSURE: Antonio Salud II, None.

Antonio V. Salud II MD * Nathan Dean MD University of Utah, Salt Lake City, UT

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Duloxetine
Home Contact Resources Exchange Links ebay